SpringWorks Therapeutics, Inc. stock is up 9.77% since 30 days ago. The next earnings date is Feb 27, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 100% of the previous 4 November’s closed higher than October. In the last 4 Unusual Options Trades, there were 4 CALLs. 100% of analysts rate it a buy.
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors.